Reach Us +1-947-333-4405


Biomarkers In Cancer Immunotherapy | 92065
ISSN: 2161-0681

Journal of Clinical & Experimental Pathology
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Google scholar citation report
Citations : 1147

Journal of Clinical & Experimental Pathology received 1147 citations as per google scholar report

Journal of Clinical & Experimental Pathology peer review process verified at publons
Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • JournalTOCs
  • Ulrich's Periodicals Directory
  • RefSeek
  • Hamdard University
  • OCLC- WorldCat
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
Share This Page

Biomarkers in cancer immunotherapy

Joint Event on 6th World Congress and Expo on Breast Pathology and Cancer Diagnosis & 20th International Conference on Medicinal Chemistry and Rational Drugs

Paola Ferrari

University Hospital of Pisa, Italy

Keynote: J Clin Exp Pathol

DOI: 10.4172/2161-0681-C3-050

Immunotherapy has gained increasing consent in different types of advanced and/or metastatic cancer. More recently, checkpoint inhibitors have been extensively studied and in some cases they have been approved by regulatory authorities for cancer therapy. However, only a minority of patients exhibits a durable response to immunotherapy, while toxicity and costs of these treatments are not insignificant. In this view, biomarkers predicting response, resistance and toxicity should be important for a better selection of patients. PD-L1 expression, TIL identification and characterisation, mutation load, microsatellite instability, MDSCs, IDO, IFN-gamma/Jak pathway mutations are some of these markers. Due to the complexity of immune response, the identification of reliable markers is difficult and research is in progress.

Paola Ferrari graduated in Medicine and Surgery at Pisa University in 1995 (full marks), specialized in Internal Medicine in 2000, PhD in Medical Physiopathology and Pharmacology. She works as medical oncologist at Unit of Oncology 1, Department of Oncology, New Technologies and Transplantations, University of Pisa. Clinical activity: Follow-up and therapy of cancer patients, mainly breast cancer patients. Principal fields of research: Breast and gastrointestinal cancer follow-up and therapy, breast cancer biomarkers and prognostic factors, cancer immunology, circulating tumor cells, cancer stem cells. Paola Ferrari is author/co-author of about 50 articles in peer reviewed journals. She regularly serves as reviewer for international oncology journals.

E-mail: [email protected]